Abbott Faces $219M FCA Trial Over Off-Label Stent Marketing
A former Abbott Laboratories sales director on Tuesday told a Texas federal jury the company charged Medicare $219 million for unauthorized uses of its stents, as a decade-old False Claims Act...To view the full article, register now.
Already a subscriber? Click here to view full article